Clinical Pharmacology & Biopharmaceutics
Open Access

Pediatric drug dosing presents significant challenges due to the unique physiological differences between children and adults, including variations in body size, organ function, and metabolic rates. These differences, along with the limited availability of clinical data specific to pediatric populations, often result in suboptimal dosing regimens. As a result, children are at an increased risk for adverse drug reactions, therapeutic failures, or ineffective treatments. The need for improved strategies for pediatric drug dosing has led to the development of model-informed dose optimization (MIDO) approaches, which rely on pharmacokinetic (PK) and pharmacodynamic (PD) models to predict drug behavior and therapeutic outcomes in pediatric patients [1].

MIDO combines mathematical models with patient-specific data to provide individualized dosing recommendations, helping to bridge the gap between available clinical knowledge and the variability seen in pediatric populations. These models account for the dynamic changes in a child’s physiology as they grow, thus enabling more accurate predictions of drug absorption, distribution, metabolism, and excretion. Such approaches allow for optimized dosing that can improve therapeutic efficacy and minimize toxicity, particularly in conditions where children have limited or no clinical trial data available for certain medications.

However, the implementation of MIDO in clinical practice presents several hurdles. These include challenges in model development and validation, integration with clinical workflows, the availability of relevant patient data, and regulatory approval. To address these issues, a systematic framework for MIDO implementation is essential. This framework should guide clinicians and researchers in the adoption of MIDO while ensuring that it is accessible, feasible, and safe for pediatric use [2].

The proposed framework in this paper aims to provide a structured approach to implementing MIDO for pediatric populations, taking into account the complexities of modeling drug behavior in children. This approach emphasizes the importance of individualized therapy, which considers not only age and weight but also other factors such as disease state, genetic variability, and environmental influences. Additionally, the framework will highlight key strategies for data collection, model development, and continuous model refinement, all of which are crucial for ensuring the accuracy and applicability of MIDO in real-world clinical settings.

In the following sections, we will discuss the various components of the systematic framework for MIDO, including the steps involved in model development, validation, and clinical integration. The aim is to ensure that pediatric drug dosing is not only safe but also tailored to optimize therapeutic outcomes for each child, based on their unique clinical profile.

Description

A systematic framework for implementing Model-Informed Dose Optimization (MIDO) in pediatric populations is designed to address the challenges associated with pediatric drug dosing. Given the physiological differences between children and adults, children often exhibit variations in drug pharmacokinetics (PK) and pharmacodynamics (PD), which complicates the determination of safe and effective drug doses. Inadequate or incorrect dosing in pediatric populations can lead to adverse drug reactions, therapeutic failure, or under-treatment, which underscores the need for more accurate and individualized dosing strategies [3,4].

MIDO leverages PK and PD models to predict how drugs are processed in the body, allowing for the optimization of dosing regimens based on an individual child’s characteristics, such as age, weight, organ function, and specific disease states. These models can integrate clinical trial data, historical patient data, and other relevant information to generate dosing recommendations that are personalized to each pediatric patient. By using MIDO, clinicians can better account for the differences in metabolism and drug sensitivity that vary widely in children due to their developmental stages [5].

The systematic framework proposed in this work is structured to ensure that MIDO can be effectively adopted and integrated into clinical practice. It begins with the development of pediatric-specific models that are built on the foundation of existing pharmacokinetic and pharmacodynamic knowledge. These models must be validated and tailored to reflect the unique pharmacological properties of drugs in children. This requires careful consideration of various factors, such as ontogeny (developmental changes), disease conditions, and genetic variations that may influence drug response in pediatric patients [6,7].

The framework also emphasizes the importance of continuous model refinement, ensuring that as new clinical data emerges, models can be updated to maintain their predictive accuracy. A key component of the framework is the incorporation of real-time patient data through electronic health records (EHR) or other clinical platforms. This allows for a dynamic and responsive dosing approach that adjusts to changes in the patient’s condition or physiological status.

For MIDO to be successfully integrated into clinical workflows, the framework proposes strategies for overcoming barriers such as regulatory hurdles, clinician training, and the integration of advanced modeling tools into existing healthcare infrastructures. It also stresses the need for collaboration between clinicians, researchers, and regulatory bodies to ensure that the benefits of MIDO can be realized safely and effectively [8,9].

Finally, the framework underscores the importance of regulatory considerations in the approval and widespread adoption of MIDO. This includes compliance with standards set by health authorities, such as the FDA or EMA, and the development of guidelines that promote safe, evidence-based implementation in pediatric populations. The ultimate goal of the systematic framework is to ensure that MIDO can be used to optimize drug dosing in pediatric patients, thereby improving therapeutic outcomes while minimizing the risks of adverse effects [10].

Discussion

The implementation of Model-Informed Dose Optimization (MIDO) in pediatric populations represents a significant advancement in precision medicine, offering the potential to tailor drug dosing strategies to individual children’s needs. Given the complex physiological differences between children and adults, such as varying metabolic rates and organ development stages, a one-size-fits-all approach to pediatric drug dosing is inadequate. MIDO offers a more precise alternative by integrating pharmacokinetic (PK) and pharmacodynamic (PD) models that account for these variations. However, the adoption of MIDO requires addressing several critical challenges.

First, the development of robust and accurate pediatric-specific models is essential. Children’s physiological characteristics evolve rapidly, and models must be designed to accommodate these developmental changes over time. Models based on adult populations may not be directly applicable, as drug metabolism and response in pediatric patients can vary widely depending on age, weight, and disease state. The integration of ontogeny data, genetic factors, and biomarkers specific to pediatric patients is crucial for developing accurate models. Furthermore, ensuring that these models are validated in diverse pediatric subpopulations remains a significant hurdle.

Second, the collection and integration of high-quality data are fundamental for model development and refinement. Given the limited availability of pediatric clinical trial data, it is necessary to leverage existing healthcare data, including electronic health records (EHRs), to support MIDO. However, challenges such as incomplete or inconsistent data and privacy concerns may limit the effectiveness of these data sources. Advanced data-sharing agreements, better data standardization, and collaboration between academic institutions, healthcare providers, and industry stakeholders could help overcome these barriers.

Third, real-time application of MIDO in clinical settings presents logistical challenges. Pediatric care involves varying patient conditions, and continuous monitoring of a child’s response to treatment is critical. A systematic framework for integrating MIDO tools into clinical workflows is necessary to facilitate easy access and use by healthcare professionals. This integration must be user-friendly and involve clinicians who are properly trained in pharmacometrics and model-informed approaches. A barrier to widespread adoption may also be the perceived complexity of the models, especially in settings with limited resources or access to computational tools.

Another significant concern is regulatory approval and the need for clear guidelines. Regulatory agencies like the FDA and EMA must establish clear standards for the validation and use of MIDO in pediatric dosing. This includes assessing the efficacy and safety of models and ensuring that the implementation of MIDO does not introduce undue risk to pediatric patients. There is also a need for frameworks that support rapid iteration and continuous refinement of models, as new data emerges or as treatments evolve.

Furthermore, ensuring that MIDO enhances the therapeutic outcomes of pediatric drug therapy must be the central focus. While individualized dosing offers the potential for improved efficacy, it is also crucial to ensure that MIDO minimizes the risk of underdosing or overdosing, which are particularly detrimental in pediatric populations. Moreover, the integration of MIDO could lead to more cost-effective healthcare by reducing adverse drug reactions and optimizing treatment outcomes.

Ultimately, successful implementation of MIDO will require collaboration among pediatricians, pharmacologists, data scientists, and regulatory agencies to overcome these challenges. As more pediatric-specific data become available, and as computational modeling tools improve, the systematic framework for MIDO will evolve, offering more personalized and safer drug therapies for children. The potential benefits of this approach include improved drug efficacy, reduced adverse effects, and more efficient clinical practices in pediatric healthcare.

Conclusion

The systematic framework for implementing Model-Informed Dose Optimization (MIDO) in pediatric populations offers a promising solution to the longstanding challenges of pediatric drug dosing. As children differ significantly from adults in terms of physiological characteristics and drug metabolism, traditional dosing strategies often fall short of providing safe and effective treatment. By leveraging advanced pharmacokinetic (PK) and pharmacodynamic (PD) models, MIDO allows for more personalized and accurate dosing tailored to the specific needs of pediatric patients. This approach holds the potential to significantly enhance therapeutic outcomes, reduce adverse effects, and optimize the use of available medications.

However, the successful implementation of MIDO in clinical practice requires overcoming several challenges. First, there is a critical need for the development of robust, pediatric-specific models that accurately reflect the dynamic changes in drug pharmacology as children grow and develop. Such models must incorporate a broad range of factors, including ontogeny, genetic variability, and disease-specific considerations. The validation of these models across diverse pediatric subpopulations is essential to ensure their broad applicability and effectiveness.

Second, the integration of real-time patient data, including electronic health records (EHR), is vital for making MIDO a practical tool in clinical settings. Data collection must be comprehensive, standardized, and of high quality to support accurate model predictions. The implementation of MIDO will require a collaborative effort between clinicians, researchers, regulatory bodies, and healthcare providers to ensure that it is feasible and beneficial for all involved.

Furthermore, regulatory guidelines for the validation and approval of MIDO tools will play a pivotal role in ensuring that these strategies are adopted safely and efficiently in pediatric care. Regulatory agencies must establish clear frameworks for the use of MIDO, which includes addressing safety, efficacy, and data privacy concerns. As MIDO tools are integrated into clinical workflows, clinicians must receive proper training to effectively apply these tools in practice, ensuring that the models are used accurately and appropriately for each patient.

Lastly, the future of MIDO in pediatric populations will depend on continued advances in computational modeling, the availability of more pediatric-specific data, and the growing integration of personalized medicine into routine healthcare. Over time, the systematic framework outlined in this work can evolve to incorporate new insights, improving dosing strategies and clinical outcomes for children. With ongoing research, collaboration, and regulatory support, MIDO has the potential to revolutionize pediatric drug therapy, providing safer, more effective treatments tailored to the unique needs of pediatric patients. Through these efforts, MIDO can ultimately contribute to optimizing the therapeutic potential of medications, reducing risks, and improving the overall quality of pediatric healthcare.

Conflict of interest

None

Acknowledgment

None

1. Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R (2022) Clinical Trial Design in the Era of Precision Medicine. Genome Med 14: 101.

Indexed at, Google Scholar, Crossref

2. Shaya J, Kato S, Adashek JJ, Patel H, Fanta PT, et al. (2023) Personalized Matched Targeted Therapy in Advanced Pancreatic Cancer: A Pilot Cohort Analysis. NPJ Genom Med 8: 1.

 Indexed at, Google Scholar, Crossref

3. Offin M, Liu D, Drilon A (2018) Tumor-Agnostic Drug Development. Am Soc  Clin  Oncol  Educ  Book.   Am  Soc  Clin  Oncol  Annu  Meet  38: 184-187.

 Indexed at, Google Scholar, Crossref

4. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, et al. (2014) First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N  Engl J Med 371: 2167-2177.

Indexed at, Google Scholar, Crossref

5. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. (2015) Dabrafenib and Trametinib versus Dabrafenib and Placebo for Val600 BRAF-Mutant Melanoma: A Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. Lancet 386: 444-451.

Indexed at, Google Scholar, Crossref

6. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. Lancet 393: 1819-1830.

Indexed at, Google Scholar, Crossref

7. Robert C, Long GV, Brady B, Dutriaux C, Maio M, et al. (2015) Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N  Engl  J  Med 372: 320-330

 Indexed at, Google Scholar, Crossref

8. Sikalidis AK (2015) Amino Acids and Immune Response: A Role for Cysteine, Glutamine, Phenylalanine, Tryptophan and Arginine in T-Cell Function and Cancer?  Pathol Oncol Res 21: 9-17.

Indexed at, Google Scholar, Crossref

9. Li X, Pasche B, Zhang W, Chen K (2018) Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncol 4: 1691-1698.

Indexed at, Google Scholar, Crossref

10. Ji L, Chen S, Gu L, Zhang X (2020) Exploration of Potential Roles of m6A Regulators in Colorectal Cancer Prognosis. Front. Oncol 10: 768.

Indexed at, Google Scholar, Crossref